633 related articles for article (PubMed ID: 32979987)
21. Stepwise management of COPD: What is next after bronchodilation?
Miravitlles M; Matsunaga K; Dreher M
Ther Adv Respir Dis; 2023; 17():17534666231208630. PubMed ID: 37936381
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
23. Treatment patterns in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL).
Yang T; Cai B; Cao B; Kang J; Wen F; Chen Y; Jian W; Wang C
Ther Adv Respir Dis; 2023; 17():17534666231158283. PubMed ID: 37013442
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics, treatment patterns, disease burden, and persistence/adherence in patients with asthma initiating inhaled triple therapy: real-world evidence from Japan.
Suzuki T; Fairburn-Beech J; Sato K; Kaise T
Curr Med Res Opin; 2020 Jun; 36(6):1049-1057. PubMed ID: 32363945
[No Abstract] [Full Text] [Related]
25. Impact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort study.
Manoharan A; Short PM; Anderson WJ; Lipworth BJ
Lung; 2014 Oct; 192(5):649-52. PubMed ID: 24952426
[TBL] [Abstract][Full Text] [Related]
26. Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.
Wurst KE; Shukla A; Muellerova H; Davis KJ
COPD; 2014 Sep; 11(5):521-30. PubMed ID: 24945236
[TBL] [Abstract][Full Text] [Related]
27. Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids.
Liao PA; Pan SW; Chen CY; Deng CY; Dong YH
Int J Chron Obstruct Pulmon Dis; 2023; 18():553-563. PubMed ID: 37069844
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and Safety of Inhaled Corticosteroids in Older Individuals with Chronic Obstructive Pulmonary Disease and/or Asthma. A Population Study.
Kendzerska T; Aaron SD; To T; Licskai C; Stanbrook M; Vozoris NT; Hogan ME; Tan WC; Bourbeau J; Gershon AS
Ann Am Thorac Soc; 2019 Oct; 16(10):1252-1262. PubMed ID: 31298938
[No Abstract] [Full Text] [Related]
29. Overuse of long-acting β
Brunton SA; Hogarth DK
Postgrad Med; 2023 Nov; 135(8):784-802. PubMed ID: 38032494
[TBL] [Abstract][Full Text] [Related]
30. Use of ICS/LABA Combinations or LAMA Is Associated with a Lower Risk of Acute Exacerbation in Patients with Coexistent COPD and Asthma.
Su VY; Yang KY; Yang YH; Tsai YH; Perng DW; Su WJ; Chou KT; Su KC; Yen YF; Chen PC
J Allergy Clin Immunol Pract; 2018; 6(6):1927-1935.e3. PubMed ID: 29432960
[TBL] [Abstract][Full Text] [Related]
31. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
Meeraus W; Wood R; Jakubanis R; Holbrook T; Bizouard G; Despres J; Silva CCD; Nachbaur G; Landis SH; Punekar Y; Aguilaniu B; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2019; 14():51-63. PubMed ID: 30587961
[TBL] [Abstract][Full Text] [Related]
32. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.
Suissa S; Dell'Aniello S; Ernst P
Chest; 2020 Apr; 157(4):846-855. PubMed ID: 31759966
[TBL] [Abstract][Full Text] [Related]
33. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
34. A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease.
D'Urzo A; Donohue JF; Kardos P; Miravitlles M; Price D
Expert Opin Pharmacother; 2015; 16(12):1845-60. PubMed ID: 26194213
[TBL] [Abstract][Full Text] [Related]
35. Association between Inhaled β
Amegadzie JE; Gamble JM; Farrell J; Gao Z
Int J Chron Obstruct Pulmon Dis; 2022; 17():1205-1217. PubMed ID: 35645559
[TBL] [Abstract][Full Text] [Related]
36. Comparative cardiovascular safety of LABA/LAMA FDC versus LABA/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework.
Chen CY; Pan SW; Hsu CC; Liu JJ; Kumamaru H; Dong YH
Respir Res; 2023 Sep; 24(1):239. PubMed ID: 37775734
[TBL] [Abstract][Full Text] [Related]
37. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma.
Anderson DE; Kew KM; Boyter AC
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD011397. PubMed ID: 26301488
[TBL] [Abstract][Full Text] [Related]
38. Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey.
Ding B; Small M
Int J Chron Obstruct Pulmon Dis; 2017; 12():1753-1763. PubMed ID: 28670116
[TBL] [Abstract][Full Text] [Related]
39. Inhaled Pharmacotherapy and Stroke Risk in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Population Based Study Using Two-Stage Approach.
Lin HW; Chung CL; Lin YS; Yu CM; Lee CN; Bien MY
PLoS One; 2015; 10(7):e0130102. PubMed ID: 26158649
[TBL] [Abstract][Full Text] [Related]
40. Inhaled corticosteroids with combination inhaled long-acting beta
Tan DJ; White CJ; Walters JA; Walters EH
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD011600. PubMed ID: 27830584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
